Neostigmine Methylsulfate Injection shortage
To Be Discontinued 1 presentations · 1 manufacturers · first FDA posting 2026-01-12 · last update 2026-01-12
Manufacturers: Fresenius Kabi USA, LLC
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10) | Fresenius Kabi USA, LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 01/12/2026 Updated 01/12/2026 Discontinued 01/12/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)